Drug · DIN 02468425
SHINGRIX
HERPES ZOSTER VACCINE (NON-LIVE RECOMBINANT, AS01B ADJUVANTED)
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 2, 2018; first marketed January 2, 2018.
- Drug Identification Number (DIN)
- 02468425
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Varicella zoster vaccines J07BK
- Class
- Human
- Record last updated
- September 4, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN | 50 MCG | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 13, 2017: NOC 19911New Drug Submission (NDS)
Other DINs named SHINGRIX
- DIN 02570270 · Approved